Genmab downgraded after HuMax-CD20 success brings "unneccesary" R&D cost rise
This article was originally published in Scrip
Executive Summary
Cannacord Adamsanalysts have revised their recommendation for Genmabfrom buy to hold, following the company's recent stock price appreciation attributed to positive HuMax-CD20 (ofatumumab) Phase III chronic lymphocytic leukaemia (CLL) results. The analysts said that while they recognise Genmab's recent clinical success and other positive news about the company this year, they still had concerns.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.